ESR1 and breast carcinoma: Here, we reveal that IGF‐1R pathway activation may be disadvantageous for the efficacy of adjuvant tamoxifen in postmenopausal ER+ breast cancer patients and that blocking this activated pathway may reverse this mechanism of endocrine therapy resistance.